liver cirrhosis

[European Journal of Immunology] Serum soluble CD137 (sCD137) is associated with inflammatory states, and positively correlated with serum tumor necrosis factor in cirrhotic hepatitis C virus (HCV) patients following virus eradication. Researchers argued against a role of sCD137 in HCV infection and suggested a function of sCD137 in liver cirrhosis.

[Hepatology International] Therapy of umbilical cord-derived MSC was not only well tolerated, but also significantly improved long-term survival rate, as well as the liver function in patients with Hepatits B Virus-related decompensated liver cirrhosis.

[EpicentRx, Inc.] EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,906,957 entitled "Immunomodulatory Fusion Proteins."

[Biomedicine & Pharmacotherapy] The authors describe the mechanism of the succinate–GPR91 signaling pathway in NASH and summarize the drugs that act on this pathway, with the aim of providing a new approach to NASH treatment.

[Journal of Cellular and Molecular Medicine] Liver SMAD2 phosphorylation was down-regulated in all series with matrix metalloproteinase (MMP) inhibition or knock-out, and MMP-9 inhibition or deletion ameliorated the severity of cirrhosis, portal hypertension, and associated derangements.

[Science Translational Medicine] Investigators used multiomics analysis of human cirrhotic liver, a Western diet – and carbon tetrachloride – induced minipig nonalcoholic steatohepatitis model, and genetically modified mice to unravel the landscape of the vascular adaptome at the single-cell level, in which endothelial cells and TH17 cells jointly contributed to liver cirrhosis.